Awareness of Meningococcal disease among travelers from the United Kingdom to the meningitis belt in Africa by Goodman, Anna L. et al.
Am. J. Trop. Med. Hyg., 91(2), 2014, pp. 281–286
doi:10.4269/ajtmh.13-0763
Copyright © 2014 by The American Society of Tropical Medicine and Hygiene
Awareness of Meningococcal Disease among Travelers from the United Kingdom
to the Meningitis Belt in Africa
Anna L. Goodman,* Cristina Masuet-Aumatell, Jay Halbert, and Jane N. Zuckerman
Department of Infection and Immunity and World Health Organization Collaborating Centre for Reference,
Research and Training in Travel Medicine, University College London, London, United Kingdom;
International Health Centre, Preventive Medicine Department, Bellvitge Hospital, L’Hospitalet De Llobregat, Barcelona, Spain;
Department of Paediatrics, University College London Hospitals, London, United Kingdom
Abstract. Meningococcal disease causes considerable morbidity and has a high case-fatality rate. In the United
Kingdom, the meningococcal quadrivalent vaccine is recommended for travelers visiting the meningitis belt of Africa. We
analyzed 302 responses to a cross-sectional study conducted in 2010 of travelers who had visited the meningitis belt recently
or were shortly due to travel there. Using the results of an online questionnaire, we assessed knowledge and understanding
of meningococcal disease and likelihood of uptake of meningococcal immunization before travel. Meningococcal vaccine
uptake was 30.1%. Although global scores in the questionnaire did not correlate with vaccine uptake, knowledge of the
meningitis belt and knowledge of certain key symptoms or signs were statistically associated with high vaccine uptake. We
conclude that improved education of travelers may improve vaccine uptake before travel to the meningitis belt in Africa.
INTRODUCTION
Meningococcal disease causes vaccine-preventable travel-
related ill health1 and the risk is increased, particularly for
persons visiting areas with a higher incidence of disease and
during outbreaks.2 The estimated incidence of meningococcal
infection in travelers is 0.04 cases/100,000 persons per month of
stay, but the incidence can be as high as 200–640/100,000 per
month of stay in high-risk groups, such as travelers to Mecca
during an outbreak.3,4 Case-fatality rates have been as high as
4.9% in the United Kingdom5 and at similar or higher levels
in Africa.6,7 Uptake of vaccination remains low and the severity
of the disease is underestimated.8 The meningitis belt of sub-
Saharan Africa involves 21 countries (Figure 1) and stretches
from Senegal in the west across to Ethiopia in the east. In this
region, meningitis is endemic and travelers are recommended
to receive a meningococcal vaccine before travel.
Meningococci are classified into serogroups according to the
immunologic reactivity of their capsular polysaccharides. In the
United Kingdom, the meningococcal quadrivalent vaccine is
recommended for travelers to the meningitis belt in Africa
because it provides protection against meningococcal sero-
groups A, C, W135 and Y (Men ACWY).9 Serogroup B is not
common in the meningitis belt and the new vaccine against this
serogroup is not yet widely available. The quadrivalent vaccine
is particularly recommended for long-stay travelers and high-
risk travelers, such backpackers and travelers living or working
in close proximity with the local population.9 In the United
Kingdom, infants are currently immunized against meningitis
serogroup C (MenC) as part of their childhood immunization
schedule, along with vaccines against other causes of bacte-
rial meningitis (Streptococcus pneumoniae and Haemophilus
influenzae); since 2013, a booster immunization has been offered
to persons 14 years of age. Adults in the United Kingdom
would not have received a vaccine at birth but instead may
have received immunization against MenC during a catch-up
campaign. Therefore, at the time of this study in 2010, only
persons < 33 years of age would have been offered MenC as
part of their routine immunizations if they had been living in
the United Kingdom during childhood.
Although studies have been performed to assess travelers’
knowledge, attitudes, and practice with respect to vaccination,
these studies have not previously focused specifically on
meningococcal meningitis.8 This study sought to determine
awareness of meningitis in travelers from the United Kingdom
who visited the meningitis belt, and whether awareness of
symptoms, strains, and mode of transmission might predict
likelihood to receive a meningococcal vaccine before travel.
The aim of the study was to explore the factors that predict
meningococcal immunization uptake before travel. The pri-
mary objective was to determine if an increased knowledge of
meningitis in travelers was associated with increased likeli-
hood of meningococcal vaccine uptake before travel. Second-
ary objectives were to determine features that limited access
to vaccination and to determine the impact of demographic
features on the likelihood of meningococcal vaccine uptake.
MATERIALS ANDMETHODS
Study design. A cross-sectional study was conducted by
using an online questionnaire-based survey of British travelers.
The questionnaire was designed by Novartis (New York, NY)
and was distributed to participants by Lightspeed Market
Research Company (Wimbledon, United Kingdom) and their
online panel members in the United Kingdom during a seven-
day period in February 2010. The online panel consists of
persons who had previously registered as interested in partici-
pating in such online surveys. The Lightspeed online panel
identified travelers who had traveled to at least one country in
the meningitis belt of Africa within the last three years, or
planned to do so within the next six 6 months. The survey was
sent to these members and no financial incentives were pro-
vided to panel members and their participation in the survey
was voluntary. Panelists provided signed informed consent
to take part in the study and the data was anonymized and
analyzed by the authors.
Questionnaire. The online questionnaire was designed to
collect information regarding the travelers background socio-
demographics; their awareness of the risks of meningococcal
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disease; whether and where they sought pre-travel health
advice; and their destination, duration and purpose of travel.
Possible responses were dichotomous to increase response
rate and question comprehension. Travelers’ awareness of the
risks of meningococcal disease were assessed through ques-
tions assessing their knowledge of potential disease symptoms,
methods of transmission, risk factors, and geographic distribu-
tion. A global knowledge score was calculated based upon
11 of the questions; each question scored one point. Social
class was classified by using the Registrar General occu-
pational classes I to V, in which I is the highest and V
is the lowest.10
Statistical analysis. Tests of normality (Kolmogorov–
Smirnov test) were applied to the data. Parametric or non-
parametric analyses were then performed according to these
results. The chi-square test was used for qualitative compari-
sons with normal distribution data, or Fisher’s exact test
when required. To adjust for potential confounders, the
demographic covariates age and reason for travel, which
were found to be significantly associated (P < 0.05) with
the dependent variable (meningitis vaccination) in the bivar-
iate analysis, were considered for inclusion in the binary
logistic regression analysis. Only statistically significant vari-
ables without interactions were then included in the final
model. Age was stratified in the bivariate analysis to facili-
tate interpretation.
The magnitude of the association between the outcome
(meningitis vaccination) and the explanatory variables was
measured by chi-square or Fisher’s exact tests, as appropriate
The model’s ability to discriminate between groups was
assessed with the area under the curve; the model’s calibra-
tion was examined by using the Hosmer and Lemershow tests.
All tests were two-tailed, and a P value < 0.05 was defined as
statistically significant. All analyses were conducted using
SPSS software version 12.0 (SPSS, Chicago, IL).
RESULTS
Demographic profile. Responses were received from 302
British travelers visiting the meningitis belt from England
(83.8%), Scotland (8.6%) and Wales (7.6%). Those persons
who responded to the survey were predominantly male
(53.6%); 35–64 years old (68.6%); belonged to social classes I
and II (56.3%); employed (80.3%); traveling for a resort or
safari holiday (57.3%); traveling for a duration of 7–14 days
(62.9%); and had previous travel experience to Africa (62.9%).
One participant stated their purpose of travel was employment
as a health care worker.
The gender distribution of the group that responded to the
survey was not significantly different from the expected pop-
ulation in the United Kingdom 15–65 years of age.11 The
population that responded to the survey were of a more afflu-
ent social class, with more respondents in class I and II than
the UK population, as determined by comparison with an
IPSOS MORI (London, United Kingdom) survey of travelers
(P < 0.0001, by chi-square test) and were more affluent than
found in a previous survey of travelers to malaria-endemic
regions (P < 0.0001).12 This finding may be caused by the
considerable costs of travel from the United Kingdom to the
meningitis belt of Africa, and in the survey of travelers to
malaria-endemic areas, such travelers were found to have a
higher median income that those who had not traveled to
such areas.
Figure 1. Meningitis belt and areas at high epidemic risk in 2012. Meningitis belt is shown in dark grey. Extracted from http://apps.who.int/
ithmap/. Reproduced with kind permission of the World Health Organization.
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Reasons for travel were similar in our survey than in
those seen in the survey of travelers to malaria-endemic
regions.12 There was no statistical difference in overall reason
for travel (business or leisure), but significantly less of our
population traveled to visit friends and relatives than those
visiting malaria-endemic regions (P < 0.001). The most common
country in Africa that the travelers in our study had visited
within the previous three years or were planning to visit in the
next six months was Kenya (46% and 35%, respectively),
followed by the Gambia (19%, 11%), Nigeria (13%, 12%),
Ghana (11%, 12%) and Uganda (10%, 10%). Underlying
health co-morbidities were not ascertained.
Sources of travel advice. More than two-thirds (71.2%) of
the travelers had consulted their general practitioner (GP) for
travel health advice. Others had consulted travel clinics (8.9%)
and the internet (12.3%) for travel health information. Only
7.6% of respondents reported seeking no travel health advice.
Travelers who were visiting friends and relatives (n = 67,
22.2%) tended to travel for a longer duration (P = 0.001);
consulted their GP or travel clinics for travel health advice
less frequently (P = 0.046); and had made more prior visits
to Africa (P = 0.002) than other types of travelers. Travelers
who were backpackers (n = 28, 9.3%) were more likely to be
male (P = 0.026), younger (P < 0.001), and seek travel health
information from travel clinics (P = 0.014) or the internet
(P = 0.002) than other types of travelers.
Meningococcal vaccination. Most (n = 157, 52%) travelers
did not plan to be immunized against meningococcal meningitis
before travel. However, 36 participants (22.9%) reported that
they had previously received an effective vaccine (Figure 2).
These 36 participants were therefore subsequently included in
the vaccinated group. Meningococcal vaccination uptake by
travelers before travel to the meningitis belt (or the intention
to receive the vaccine before travel for travelers planning to
travel to the meningitis belt within the next six months) was
30.1% (n = 91). The remaining 17.9% (n = 54) of travelers
could not recall if they were vaccinated before travel or were
unsure if they were planning to be vaccinated. The rate of
uptake of vaccination was highest in travelers < 35 years of
age, backpackers, business travelers, and those who had previ-
ously traveled to a country in Africa. The strength of relation-
ship between these demographic categories and vaccine uptake
is shown in Table 1. Vaccine uptake was increased in those
with knowledge of the geographic distribution of meningo-
coccal disease.
Meningococcal vaccine acceptability. Among those 157
travelers who were not vaccinated and who did not intend to
be vaccinated, the reasons given included that the participant
had previously received the vaccine, which remained effective;
the GP and/or travel medicine specialist did not recommend
the vaccine; the traveler did not consider the vaccine to be
necessary; the traveler had previously been immunized against
meningitis; the traveler decided to take a risk; the traveler did
not feel there was sufficient time to be immunized before
travel; and the traveler considered the vaccine too expensive
(Figure 2).
Disease attitudes and knowledge. We assessed travelers’
awareness of potential infectious disease risks during a trip to
Africa. Travelers considered risks to include malaria (89%),
yellow fever (73%), rabies (47%), and dengue fever (41%).
Figure 2. Reasons given by participants to not receive quadrivalent vaccination againstNeisseria meningitidis serotypes ACWY (n = 157). This
chart depicts reasons selected by those who chose not to be vaccinated before (n = 157). Data shown are number (N) of survey respondents and the
graph shows their primary reason for not receiving or planning to receive a vaccine before travel. GP = general practitioner.
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Only one-third of travelers agreed that there was a risk of
meningitis when traveling to Africa. This knowledge was
increased among those who had visited Africa previously
(41%), traveled/were traveling for durations > 14 days (43%),
and those who were vaccinated or planned to be vaccinated
against meningitis (59%).
A total of 60.8% of our sample of travelers had never
previously heard of the meningitis belt. Travelers were less
likely to have heard of the meningitis belt if they had not been
vaccinated (73%) and/or had not previously visited Africa
(70%). Approximately one-third of those questioned (32.8%)
stated that they had heard of the meningitis belt but were
unable to name a single country in the region.
Knowledge of meningococcal meningitis was analyzed.
Most travelers questioned were aware of the symptoms and
signs of spots/rash and fever (73%), neck stiffness (66%), and
photophobia (62%). Few travelers were aware of shortness of
breath (21.8%) as a possible symptom of disease.
More than one-third (37.4%) of respondents were aware
of the presence of multiple strains of Neisseria meningitidis.
Fifty-seven percent of travelers were aware of the risk of
invasive infection or carriage and the risk of transmission to
family and friends on returning home.
Travelers’ global knowledge of meningitis was similar in
vaccinated and unvaccinated groups (P = 0.563). Vaccinated
travelers’ knowledge regarding meningitis was greater than
that of unvaccinated travelers’ concerning the potential symp-
toms of spots, breathlessness and cold hands (P < 0.001); differ-
ent microbiologic strains (P = 0.009); and the risk of exposure
to meningitis in Africa (P < 0.001).
Persons visiting friends and relatives had a similar global
knowledge of meningitis to other types of travelers (P = 0.724)
though they had lower levels of knowledge regarding potential
symptoms and risk of transmission or carriage (P = 0.020).
Persons visiting friends and relatives had a similar uptake
of meningitis vaccine to other types of travelers (37.5%;
P = 0.094).
Backpackers had a similar global knowledge of meningitis
compared with other types of travelers (P = 0.709), including
the risk of transmission or carriage (P = 0.511). However, they
had statistically significantly higher levels of knowledge
regarding symptoms of meningitis (breathlessness P = 0.001,
cold hands P = 0.003, spots P = 0.002); the different meningo-
coccal strains (strain W135; P = 0.024); and risk of exposure in
Africa (P = 0.028). They were more likely to be vaccinated
than other groups of travelers (50.0%; P = 0.003). In this
cohort, 39% of travelers traveling to the meningitis belt for >
30 days were vaccinated in comparison to 29.4% of travelers
who traveled for < 30 days (P = 0.328).
DISCUSSION
The objective of this study was to investigate the knowl-
edge, attitudes, and practice of immunization against menin-
gococcal disease in travelers to the meningitis belt of Africa.
This study demonstrated that knowledge regarding meningo-
coccal infection in travelers was low: mean score of 6.96
(63.3%) of 11 on a questionnaire. Such low levels of aware-
ness were similar to those described in other studies.13,14 Lack
of knowledge occurred even among those at particular risk of
meningococcal infection, such as travelers who are travelers
visiting friends and relatives, backpackers, and adolescents
(14–25 year old).
Traveler’s awareness of the risk of contracting meningococ-
cal disease13 is low, particularly when compared with their
understanding of other travel-related infections, such as
malaria and yellow fever, and these findings were confirmed
by this study.14 Travelers visiting friends and relatives often
have a poor understanding of their risk of infection during
travel.15 This study demonstrated that travelers visiting friends
and relatives, in particular, were less likely to seek pre-travel
health advice, although they were no less likely than other
travelers to seek vaccination against meningitis. Other studies
have found that travelers visiting friends and relatives were less
likely to seek pre-travel health advice and receive travel vacci-
nations, and yet are more likely to be at increased risk of
exposure to infections because of their staying in closer prox-
imity to local communities for longer durations in developing
countries.16 Meningococcal vaccines are administered less
frequently in travelers visiting friends and relatives than in
tourist travelers.15
Although global knowledge scores did not correlate with
likelihood of immunization, awareness of meningitis was
associated with increased vaccine uptake. Knowledge of only
the symptoms of breathlessness, spots, or rash that does not
fade and cold hands or feet appeared to be associated with
vaccine uptake. The knowledge of spots or rash may be a
result of public health campaigns in the United Kingdom
Table 1
Demographic information and association with meningitis
vaccination status (n= 302)*
Chacteristic Specific factor
Meningitis
vaccination
not given
or status
not known
(n = 211)
No. (%)
Meningitis
vaccination
given
or planned
(n = 91)
No. (%) P†
Age, years 16–24 12 (52.2) 11 (47.8) < 0.001
25–34 34 (55.7) 27 (44.3)
35–44 58 (73.4) 21 (26.6)
45–54 45 (69.2) 20 (30.8)
55–64 54 (85.7) 9 (14.3)
³ 65 8 (72.7) 3 (27.3)
Sex M 106 (65.4) 56 (34.6) 0.071
F 105 (75.0) 35 (25.0)
Social class I 71 (73.2) 26 (26.8) 0.548
II 42 (57.5) 31 (42.5)
III non-manual 40 (76.9) 12 (23.1)
III manual 14 (70.0) 6 (30.0)
IV 3 (75.0) 1 (25.0)
V 41 (73.2) 15 (26.8)
Purpose of trip Business 24 (53.3) 21 (46.7) 0.003
VFR 46 (68.7) 21 (31.3)
Backpacking 16 (57.1) 12 (42.9)
Resort based 72 (79.1) 19 (20.9)
Safari 38 (70.4) 16 (29.6)
Volunteer
work
4 (66.7) 2 (33.3)
Other 11 (100.0) 0 (0.0)
Length of trip,
days
< 7 9 (60.0) 6 (40.0) 0.908
7–14 133 (70.0) 57 (30.0)
15–30 55 (74.3) 19 (25.7)
> 30 14 (60.9) 9 (39.1)
Previous trip
to Africa
No 83 (74.1) 29 (25.9) 0.218
Yes 128 (67.4) 62 (32.6)
*Data are no. (%) of patients, unless otherwise indicated. VFR = visiting friends
and relatives.
†P value obtained by c2 test or Fischer exact test as appropriate.
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highlighting the dangers of meningitis that were associated
with photographs of such a rash. It is surprising that knowl-
edge of breathlessness and cold hands or feet were associated
with likelihood of vaccination but symptoms of stiff neck and
fever were not. An association was found between a lack of
knowledge of the meningitis belt and lack of awareness of
the possibility of exposure in Africa, and a failure to seek
vaccination. A logistical regression model was able to predict
vaccine uptake by including the following factors: age; those
who had not heard of the meningitis belt; those who were not
aware they could be exposed to meningitis in Africa; and
those who answered symptom questions about breathlessness,
rash, and cold hands incorrectly. It is not possible to prove
causation for any of the questions included and it is possible
that those vaccinated were educated about meningitis and
provided with an explanation as to why they were being vac-
cinated at the time of immunization.
In this study, only 30.1% of travelers were vaccinated or
intended to be vaccinated against meningococcal meningitis.
A further 11.9% of travelers believed that they did not
require immunization because they had already been vacci-
nated against meningitis. These participants were included as
vaccinated in our analysis but it is possible that they had
previously received MenC. MenC would provide the traveler
with some protection against meningitis but only serogroup C,
and a traveler immunized against this type might not appre-
ciate the difference between meningitis vaccines and may
therefore believe they do not require a further meningitis vac-
cine before to travel. In this study, only 37.5% of travelers were
aware of the presence of multiple strains of N. meningitides.
A total of 37.5% of travelers visiting friends and relatives
travelers were vaccinated or intended to be vaccinated before
travel. Previous studies conducted with travelers visiting
friends and relatives showed a misperception of disease risk
and limited availability of funds to pay for the vaccine among
immigrant families in comparison to other tourists,15,17 and
such factors may have contributed to the limited uptake in our
study. Another risk factor increasing risk of infection is pro-
longed duration of travel, and travelers visiting friends and
relatives in this study were found to take longer trips abroad
than other travelers. Although the overall percentage of sus-
ceptible travelers vaccinated was low, we were encouraged by
the non-significant increase in vaccine uptake seen in those
traveling for longer periods (> 30 days).
This study had certain limitations, which included potential
selection bias because no information was received as to how
many participants were invited to be in the survey, and who
did not respond and why. When compared with the back-
ground population in the United Kingdom, our population
belonged to a more affluent social class, as might be expected
for those purchasing expensive air travel. However, when
compared with a population of travelers to malaria-endemic
area, this difference remained, which suggested possible selec-
tion bias for more affluent travelers. The overall reasons for
travel (business or leisure) were comparable with those trav-
eling to malaria-endemic areas, although our population
included less travelers visiting friends and relatives than
expected.12 The survey was only applied once in 2010 and for
a limited time frame. Although it is likely that the results
remained relevant for subsequent years, it is possible that
public health campaigns at the time affected the results and
results now would differ. The uptake of vaccination in chil-
dren was also not investigated. There is potential confounding
in that those that had been vaccinated may have been advised
about the risk of infection with meningococcal meningitis
when they were vaccinated. It therefore cannot be inferred
that the absence of advice caused lack of immunization
though an association was found. The presence in of immuno-
deficiencies and asplenia in travelers was not assessed, which
would have increased the risk of contracting meningitis. It is
assumed that travelers with such co-morbidities would be
more likely to have been immunized previously.
All travelers in this study should have received advice
regarding the risks of meningococcal disease and been offered
vaccination if there were no contraindications because of their
destination of travel to a country in the meningitis belt. Despite
50 million persons18 traveling to developing countries and
between 22% and 64% of travelers self-reporting some health
problems as a consequence of such travel,1,18 knowledge and
understanding of travel-related infections remains limited.8
Awareness of the symptoms and signs of meningococcal dis-
ease are important to ensure those affected seek help rapidly.
Vaccination is the most effective preventive strategy19 and
advice regarding the risks of meningococcal disease and a
risk-assessment for the individual traveler should be con-
ducted during a travel health consultation to ensure protec-
tion of a traveler against a serious communicable disease.
Our study demonstrates that greater knowledge of the
meningitis belt and awareness of meningococcal disease is
associated with increased uptake of meningococcal vaccina-
tion to prevent disease. We conclude that improved education
of travelers may improve vaccine uptake before travel to the
meningitis belt in Africa. Our study supports the need for
both public health campaigns to increase awareness of menin-
gococcal disease and effective communication with travelers
regarding the risks to which they may be exposed, and how
these exposures might be prevented.
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